Pharmaceutical giant Eli Lilly is joining forces with digital health platform Hims & Hers to widen access to its blockbuster obesity treatments, offering eligible patients a direct route to FDA-approved weight-loss medicines at self-pay prices starting at $149 a month.
Under the agreement, patients prescribed Lilly's Foundayo (orforglipron) or Zepbound (tirzepatide) by a licensed provider through the Hims & Hers platform will be able to access the medicines without leaving the digital healthcare platform.
The partnership brings two of Lilly's obesity treatments to one of the world's largest digital health platforms, combining online medical consultations, prescriptions and home delivery in a single service.
Monthly self-pay prices will start at $149 for Foundayo and $299 for Zepbound, according to the companies.
"At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are," said Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company.
"Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed."
The move comes amid growing interest among adults with obesity in accessing medical care and prescription treatments through telehealth services. The availability of a wider range of FDA-approved GLP-1 treatments, including Lilly's daily oral medicine Foundayo, is also reshaping the digital weight-loss market.
For Hims & Hers, the partnership represents a significant addition to its weight-loss offerings, giving its customers access to branded, FDA-approved medicines alongside its existing clinical support and follow-up services.
"Lilly is one of the most innovative pharmaceutical companies in history, and I'm incredibly proud that Hims & Hers is a part of making sure more people can access the medicines they've created," said Andrew Dudum, co-founder and CEO of Hims & Hers.
"By working together, we're not just reaching more people with obesity with seamless, personal access to FDA-approved Lilly medicine. We're showing the industry what innovators can achieve for customers everywhere when we work together to make the world well."
Under the arrangement, patients can consult licensed healthcare providers through Hims & Hers, receive a prescription if clinically appropriate and have their medication delivered directly to their homes.
The platform also offers ongoing support, including round-the-clock access to a care team, nutrition guidance, regular clinical check-ins and participation in its Weight Loss community.
Importantly, the companies said the agreement preserves independent clinical decision-making. Providers will continue to determine which treatment is appropriate for individual patients rather than being directed towards a particular medicine.
Hims & Hers also stressed that it has never offered compounded copies of Lilly's GLP-1 medicines and has committed not to do so in the future.
Foundayo is Lilly's oral obesity treatment, while Zepbound is an injectable medicine containing tirzepatide. Both are prescription treatments intended to be used alongside a reduced-calorie diet and increased physical activity.
